Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 93% Improvement Relative Risk HCQ for COVID-19  Yilgwan et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 3,462 patients in Nigeria (February 2020 - August 2021) Lower mortality with HCQ (p<0.000001) c19hcq.org Yilgwan et al., Nigerian Medical J., May 2023 Favors HCQ Favors control

Clinical profile and Predictors of Outcomes of Hospitalized Patients with Laboratory-Confirmed Severe Acute Respiratory Syndrome Coronavirus 2 in Nigeria: A Retrospective Analysis of 13 High Burden States in Nigeria

Yilgwan et al., Nigerian Medical Journal, 64:2
May 2023  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19hcq.org
Retrospective 3,462 hospitalized COVID-19 patients across 13 states in Nigiera, showing lower mortality with HCQ. Authors note that the improved results compared with many other late stage studies may be related to the dose and experience of the physicians - in other studies beneficial effects may be offset by the side effects of high cumulative doses in late stage patients. Authors also note the worse results with a combination of CQ/HCQ and AZ may be related to the side effects becoming more significant for late stage patients.
risk of death, 93.0% lower, OR 0.07, p < 0.001, treatment 1,039, control 2,423, adjusted per study, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Yilgwan et al., 11 May 2023, retrospective, Nigeria, peer-reviewed, 12 authors, study period 25 February, 2020 - 30 August, 2021.
This PaperHCQAll
Clinical profile and Predictors of Outcomes of Hospitalized Patients with Laboratory-Confirmed Severe Acute Respiratory Syndrome Coronavirus 2 in Nigeria: A Retrospective Analysis of 13 High Burden States in Nigeria
Christopher Sabo Yilgwan, Adamu Onu, Joshua Ofoli, Longji Benle Dakum, Shehu Nathan Yakubu, Dimie Ogoina, Ijeoma Okoli, Deborah Osisanwo, Vivian Okafor, Adebola Olayinka, Ibrahim Mamadu, Adebimpe Adebiyi
Background: The majority of global COVID deaths have occurred in developed countries. Not much is known about the clinical outcomes for the patients admitted with COVID in Nigeria. We thus described the clinical characteristics, outcomes, and predictors of outcomes of hospitalized Nigerian COVID-19 patients. Methodology: We performed multilevel and mixed effects regression, Kaplan-Meir survival, and Cox proportionate hazards analyses to evaluate factors associated with death in patients admitted for COVID-19 in 13 high-burden states of Nigeria between 25 th February 2020 and 30 th August 2021. Results: Of the 3462 patients (median age, 40 years (interquartile range 28 years 54 years), 2,990(60.6%) were male and, 213(6.15%) of them died while on admission. Male sex (adjusted odds ratio [aOR], 1.78 [95% confidence interval {CI}, 1.23-2.56]), age group 45-65 years (OR, 3.93 [95% CI, 1.29-12.02]), age group 66-75 years (aOR, 5.37 [95% CI,), age group > 75 years (aOR, 6.81 [95% CI, 2.04-22.82]), chronic cardiac disease (aOR, 3.07 [95% CI, 1.20-7.86]), being diabetic (aOR, 2.16 [95% CI, 1.41-3.31]), and having chronic kidney disease (OR, 11.01 [95% CI,),were strongly associated with increased odds of death. Having concurrent malaria (aOR, 0.45 [95% CI, 0.16-1.28]), use of Azithromycin for treatment (aOR, 0.33 [95% CI, 0.19-0.54]), and use of Chloroquine/Hydroxychloroquine for treatment (aOR, 0.07 [95% CI, 0.03-0.14]) were significantly associated with decreased odds of death. Conclusions: The cumulative probability of death of male patients, diabetics, hypertensives, and patients with CKD was higher than that of female patients and those without those comorbidities while concurrent malaria and use of chloroquine/hydroxychloroquine in the treatment regimen were associated with a decreased risk of dying in patients treated in our isolation centers.
Conflict of interest: None declared. Contributors Statement Dr Yilgwan CS, Shehu NY, Okoli I and Dakum L conceptualized and designed the study, analyzed the data, drafted the initial manuscript, and reviewed and revised the manuscript. Onu A designed the data collection instruments, collected data and reviewed and revised the manuscript. Dakum LB, Ogoina D and Adebiyi A supervised data collection, and critically reviewed the manuscript for important intellectual content. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work. Conclusions In this study, we found that male sex, older age of the patient, the presence of comorbidities like diabetes, and chronic heart, and kidney diseases on admission were associated with increased risk of mortality due to COVID-19 infection while concurrent malaria infection and use of chloroquine/hydroxychloroquine and azithromycin were associated with a decreased risk of mortality in patients treated in our isolation centers. This information is significant in that it updates our understanding as well as provides guidance to physicians managing patients with COVID-19 and may help to improve care for patients through risk stratification. It also helps our health policymakers in reaching public health decisions on the allocation of healthcare resources and personnel in this current and future pandemic.
References
Acharya, Liu, Gack, Dysregulation of type I interferon responses in COVID-19, Nature Reviews Immunology
Ahmad, Boschi-Pinto, Lopez, Murray, Lozano et al., Sex hormones and novel coronavirus infectious disease (COVID-19), Geneva: World Health Organization
Akinbolagbe, Otrofanowei, Akase, Akintan, Ue et al., Predictors and outcomes of COVID-19 patients with hypoxemia in Lagos, Nigeria. J Pan Afr Thorac Soc
Alasia, Maduka, Profile and Outcome of Hospitalized Patients with Severe COVID-19 in a Tertiary Hospital in Southern Nigeria, EC Pulmonology and Respiratory Medicine
Anyanwu, The association between malaria prevalence and COVID-19 mortality, BMC Infectious Diseases
Ayodele, Jimoh, Fagbamigbe, Onakpoya, The dynamics of COVID-19 outbreak in Nigeria: A sub-national analysis. Scientific African
Burke, Freeman, Cellura, Stuart, Brendish et al., Inflammatory phenotyping predicts clinical outcome in COVID-19, Respiratory research
Channappanavar, Fett, Mack, Eyck, Meyerholz et al., Sex-based differences in susceptibility to severe acute respiratory syndrome coronavirus infection, The Journal of Immunology
Chowdhury, Rathod, Gernsheimer, A rapid systematic review of clinical trials utilizing chloroquine and hydroxychloroquine as a treatment for COVID-19, Academic Emergency Medicine
Diaz-Arocutipa, Brañez-Condorena, Hernandez, QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis, Pharmacoepidemiology and Drug Safety
Erdfelder, Faul, Buchner, GPOWER: A general power analysis program. Behavior research methods, instruments, & computers
Iaccarino, Grassi, Borghi, Ferri, Salvetti et al., Age, and multimorbidity predict death among COVID-19 patients: results of the SARS-RAS study of the Italian Society of Hypertension, Hypertension
Iesa, Osman, Hassan, Dirar, Abuzeid et al., SARS-CoV-2 and Plasmodium falciparum common immunodominant regions may explain low COVID-19 incidence in the malaria-endemic belt. New microbes and new infections
Karalis, Ismailos, Karatza, Chloroquine dosage regimens in patients with COVID-19: Safety risks and optimization using simulations, Safety Science
Kenyon, Rosanas, Could malaria explain the global distribution of the angiotensin converting enzyme I/D polymorphism? A systematic review and ecological study, F1000Research
Lai, Wang, Wang, Hsueh, Ko et al., Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status, International journal of antimicrobial agents
Lapidus, Liu, Casanovas-Massana, Dai, Huck et al., Plasmodium infection induces cross-reactive antibodies to carbohydrate epitopes on the SARS-CoV-2 Spike protein, doi:10.1101/2021.05.10.21256855
Macedo, Gonçalves, Febra, COVID-19 fatality rates in hospitalized patients: systematic review and meta-analysis, Ann Epidemiol, doi:10.1016/j.annepidem.2021.02.012
Mccabe, Sahni, Ramsaha, A systematic review on the therapeutic relevance of hydroxychloroquine/chloroquine in the management of COVID-19, Indian Journal of Community Medicine: Official Publication of Indian Association of Preventive & Social Medicine
Medema, Been, Heijnen, Petterson, Implementation of environmental surveillance for SARS-CoV-2 virus to support public health decisions: Opportunities and challenges, Curr Opin Environ Sci Health, doi:10.1016/j.coesh.2020.09.006
Nachega, Ishoso, Otokoye, Hermans, Machekano et al., Clinical characteristics and outcomes of patients hospitalized for COVID-19 in Africa: early insights from the Democratic Republic of the Congo, The American Journal of tropical medicine and Hygiene
Nutley, Reynolds, Improving the use of health data for health system strengthening, Global health action
Okonji, Okonji, Mukumbang, Van Wyk, Understanding varying COVID-19 mortality rates reported in Africa compared to Europe, Americas and Asia, Trop Med Int Health, doi:10.1111/tmi.13575
Panda, Tripathy, Das, Plasmodium falciparum infection may protect a population from severe acute respiratory syndrome coronavirus 2 infection, The Journal of Infectious Diseases
Popoola, Population growth and life expectancy in Nigeria: Issues and further considerations, Humanities and Social Science Research, doi:10.30560/hssr.v1n1p30
Quaglio, Preiser, Putoto, COVID-19 in Africa, Public Health, doi:10.1016/j.puhe.2020.05.030
Schellekens, Sourrouille, COVID-19 mortality in rich and poor countries: a tale of two pandemics
Shah, Owens, Franklin, Mehta, Heymann et al., comorbidities and outcomes in hospitalized COVID-19 patients in rural southwest Georgia, Annals of Medicine
Siddiqui, Sarfraz, Rizvi, Shaheen, Yousafzai et al., Global variation of COVID-19 mortality rates in the initial phase
Ssebambulidde, Segawa, Abuga, Nakate, Kayiira et al., Parasites and their protection against COVID-19-Ecology or Immunology?, MedRxiv, doi:10.1101/2020.05.11.20098053
Tehrani, Killander, Åstrand, Jakobsson, Gille-Johnson, Risk factors for death in adult COVID-19 patients: frailty predicts fatal outcome in older patients, International Journal of Infectious Diseases
Yang, Tan, Zhou, Yang, Peng et al., Effects of angiotensin II receptor blockers and ACE (angiotensin-converting enzyme) inhibitors on virus infection, inflammatory status, and clinical outcomes in patients with COVID-19 and hypertension: a single-center retrospective study, Hypertension
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit